MedicaidPrior AuthMedium impact
Oregon Health Plan (OHP) prescribers – Changes to fee-for-service coverage of thyroid hormones effective October 1, 2022
Oregon Health Plan·OR · Endocrinology, Family Medicine, Internal Medicine·Provider
Effective date
Oct 1, 2022
We identified it
Jun 20, 2026
Summary
Oregon Health Plan (OHP) now requires prior authorization for non-preferred thyroid hormone medications including levothyroxine capsules, levothyroxine solution, thyroid pork tablets, and liothyronine tablets effective October 1, 2022. Levothyroxine sodium tablets remain the preferred product without prior authorization requirements.
Action Required
Before October 1, 2022: For OHP fee-for-service patients on non-preferred thyroid hormones (TIROSINT, THYQUIDITY, TIROSINT-SOL, ARMOUR THYROID, NP THYROID, CYTOMEL), providers must either switch patients to preferred levothyroxine tablets if medically appropriate, or submit prior authorization requests including all relevant ICD-10 diagnosis codes and documentation explaining why preferred options are not suitable. Claims will be denied without approved prior authorization.